CCSER2

Across TCGA pan-cancer cohorts, CCSER2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CCSER2 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CCSER2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCSER2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where CCSER2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	III,IV	0.303	0.780	.002	12	view →
LUAD	DFS	Median	III,IV	0.596	0.888	.011	9	view →
CCRCC	DFS	Median	All	1.000	0.877	.017	2	view →
LSCC	DFS	Median	II,III,IV	1.000	0.571	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CCSER2–PDAC (DFS)

Open the PDAC breakdown →